FIELD: biotechnology.
SUBSTANCE: invention is related to an antibody or an antigen-binding fragment of an antibody that specifically binds to CD3. A polypeptide that specifically binds to CD3, an antibody containing an antibody or an antigen binding fragment of an antibody, a nucleic acid encoding an antibody or an antigen binding fragment of an antibody or the specified polypeptide, an expression vector containing the specified nucleic acid, a host cell containing the specified nucleic acid or vector, as well as a composition for use in the treatment of a disease associated with CD3, containing the specified antibody or antigen-binding fragment of an antibody or polypeptide, are also disclosed.
EFFECT: invention is effective for activating T cells, as well as treating diseases associated with CD3.
33 cl, 38 dwg, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
ANTIBODIES SPECIFIC TO FLT3 AND THEIR APPLICATIONS | 2018 |
|
RU2758513C2 |
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
ANTIBODIES TO CERAMIDE | 2015 |
|
RU2717651C2 |
ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
HUMAN NOTCH4 ANTIBODY | 2016 |
|
RU2720280C2 |
Authors
Dates
2023-11-09—Published
2018-05-08—Filed